The TNFRSF4 molecule has been identified as a co-stimulatory agent that may significantly promote effective antitumoral responses in sarcoma, melanoma, and breast cancer, as suggested by preclinical research (183, 184). The gene discussed is TNFRSF4; the disease is melanoma.